Literature DB >> 3384629

Evaluation of human adenoviruses 38, 39, 40, and 41 as new serotypes.

J C Hierholzer1, R Wigand, J C de Jong.   

Abstract

Four new serotypes of human adenovirus (Ad38-41) have been described in recent literature. We conducted a thorough evaluation of the prototype strains of these types by preparing rabbit and horse antisera to them and performing reciprocal neutralization and hemagglutination-inhibition (HI) tests with all 41 prototype viruses and antisera. Types 38 and 39 are in subgenus D, share hemagglutinins with Ad13 and each other in three-way HI tests, and have been rarely encountered thus far; types 40 and 41 are in subgenus F, are related to each other by serum neutralization and HI tests, and are well-established agents of acute gastroenteritis in infants. All four prototype strains meet the accepted criteria for new serotypes, although special mention is made of the serologic relationship between Ad40 and 41. The horse antisera have stable titers and can serve as international reference reagents for these viruses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3384629     DOI: 10.1159/000150023

Source DB:  PubMed          Journal:  Intervirology        ISSN: 0300-5526            Impact factor:   1.763


  4 in total

1.  Restriction site mapping of adenovirus prototypes of subgenus D.

Authors:  R Wigand; T Adrian
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

2.  Intermediate adenovirus strains of subgenus D occur in extensive variety.

Authors:  R Wigand; T Adrian
Journal:  Med Microbiol Immunol       Date:  1989       Impact factor: 3.402

3.  Intermediate human adenovirus type 22/H10,19,37 as a new etiological agent of conjunctivitis.

Authors:  M Noda; Y Miyamoto; Y Ikeda; T Matsuishi; T Ogino
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

4.  Antigenic relationships among the 47 human adenoviruses determined in reference horse antisera.

Authors:  J C Hierholzer; Y O Stone; J R Broderson
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.